M2Gen®, Moffitt's wholly-owned, for-profit subsidiary, is an informatics solutions company that advances precision medicine by integrating and analyzing clinical and molecular data. Founded in 2006, M2Gen operates the Total Cancer Care® Protocol, a unique approach to studying patients throughout their lifetime. The company also manages the Oncology Research Information Exchange Network (ORIEN), a partnership with the nation’s leading cancer care institutions.
Total Cancer Care® is a research study that partners with patients who donate clinical data and tissue for molecular analysis, so that we may learn from patient experiences and develop evidence-based approaches to meet patients’ needs. Consented patients agree to be contacted for future studies, playing an active role in the study of their cancer and improving care for future generations.
Using the information learned from patients through the Total Cancer Care® Protocol, we work with biopharmaceutical companies to address the most challenging questions, from discovery to analyses of marketed therapies. At the core of what we do is a unique pro-active approach to identify and follow patients who are in need of new treatments through clinical trial matching. By creating a rapid learning environment, M2Gen accelerates the science of precision medicine by creating evidence and knowledge-based solutions that identify a patient’s susceptibility to disease, predict how patients will respond to a particular treatment, and match patients to best therapies for an optimal outcome.
Launched in May 2014, The Oncology Research Information Exchange Network (ORIENcancer.org) is a unique research partnership among top cancer centers that recognize collaboration and access to data are the keys to advancing cancer discovery, and delivering improved cancer care. Members agree to use the Total Cancer Care protocol and share multiple data sources in order to match patients to targeted treatments.
Through ORIEN, Cancer Centers serve more patients by sharing and collaboration. To date, more than 124,000 Total Cancer Care® consented patients have agreed to donate their tissue and clinical data for research to understand cancer at the molecular level.
To learn more about M2Gen, Total Cancer Care and ORIEN, visit M2Gen.com.